{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:19:41Z","timestamp":1792174781304,"version":"4.4.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The hypertrophic cardiomyopathy phenotype encompasses a heterogeneous spectrum of genetic and acquired diseases characterized by the presence of left ventricular hypertrophy in the absence of abnormal cardiac loading conditions. This \u201cumbrella diagnosis\u201d includes the \u201cclassic\u201d hypertrophic cardiomyopathy (HCM), due to sarcomere protein gene mutations, and its phenocopies caused by intra\u2010 or extracellular deposits, such as Fabry disease (FD) and cardiac amyloidosis (CA). All these conditions share a wide phenotypic variability which results from the combination of genetic and environmental factors and whose pathogenic mediators are poorly understood so far. Accumulating evidence suggests that inflammation plays a critical role in a broad spectrum of cardiovascular conditions, including cardiomyopathies. Indeed, inflammation can trigger molecular pathways which contribute to cardiomyocyte hypertrophy and dysfunction, extracellular matrix accumulation, and microvascular dysfunction. Growing evidence suggests that systemic inflammation is a possible key pathophysiologic process potentially involved in the pathogenesis of cardiac disease progression, influencing the severity of the phenotype and clinical outcome, including heart failure.\u00a0In this review, we summarize current knowledge regarding the prevalence, clinical significance, and potential therapeutic implications of inflammation in HCM and two of its most important phenocopies, FD and CA.<\/jats:p>","DOI":"10.1007\/s10741-023-10307-4","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T01:02:22Z","timestamp":1682643742000},"page":"1065-1075","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Inflammation across the spectrum of hypertrophic cardiac phenotypes"],"prefix":"10.1007","volume":"28","author":[{"given":"Rosa","family":"Lillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Graziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Franceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Iannaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Massetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Crea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Liuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"key":"10307_CR1","doi-asserted-by":"crossref","unstructured":"Rapezzi C, Arbustini E, Caforio AL et al (2013) Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J\u00a034(19):1448\u20131458","DOI":"10.1093\/eurheartj\/ehs397"},{"issue":"4","key":"10307_CR2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","volume":"79","author":"BJ Maron","year":"2022","unstructured":"Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Rowin EJ, Maron MS, Sherrid MV (2022) Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol 79(4):372\u2013389","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10307_CR3","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","volume":"77","author":"M Pieroni","year":"2021","unstructured":"Pieroni M, Moon JC, Arbustini E et al (2021) Cardiac involvement in fabry disease: JACC Review Topic of the Week. J Am Coll Cardiol 77(7):922\u2013936","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10307_CR4","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","volume":"13","author":"S Dorbala","year":"2020","unstructured":"Dorbala S, Cuddy S, Falk RH (2020) How to image cardiac amyloidosis: a practical approach. JACC Cardiovasc Imaging 13(6):1368\u20131383","journal-title":"JACC Cardiovasc Imaging"},{"issue":"18","key":"10307_CR5","doi-asserted-by":"publisher","first-page":"6462","DOI":"10.3390\/ijms21186462","volume":"21","author":"E Monda","year":"2020","unstructured":"Monda E, Palmiero G, Rubino M, Verrillo F, Amodio F, Di Fraia F, Pacileo R, Fimiani F, Esposito A, Cirillo A, Fusco A, Moscarella E, Frisso G, Russo MG, Pacileo G, Calabr\u00f2 P, Scudiero O, Caiazza M, Limongelli G (2020) Molecular basis of inflammation in the pathogenesis of cardiomyopathies. Int J Mol Sci 21(18):6462","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10307_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.742178","volume":"4","author":"FA Wenzl","year":"2021","unstructured":"Wenzl FA, Ambrosini S, Mohammed SA, Kraler S, L\u00fcscher TF, Costantino S, Paneni F (2021) Inflammation in metabolic cardiomyopathy. Front Cardiovasc Med 4(8):742178","journal-title":"Front Cardiovasc Med"},{"key":"10307_CR7","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/heartjnl-2011-300960","volume":"98","author":"J Kuusisto","year":"2012","unstructured":"Kuusisto J, Karja V, Sipola P, Kholova I, Peuhkurinen K, Jaaskelainen P, Naukkarinen A, Yla-Herttuala S, Punnonen K, Laakso M (2012) Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy. Heart 98:1007\u20131013","journal-title":"Heart"},{"issue":"21","key":"10307_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009098","volume":"7","author":"H Yogasundaram","year":"2018","unstructured":"Yogasundaram H, Nikhanj A, Putko BN, Boutin M, Jain-Ghai S, Khan A, Auray-Blais C, West ML, Oudit GY (2018) Elevated inflammatory plasma biomarkers in patients with Fabry disease: a critical link to heart failure with preserved ejection fraction. J Am Heart Assoc 7(21):e009098","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10307_CR9","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ejhf.1039","volume":"20","author":"CS Siegismund","year":"2018","unstructured":"Siegismund CS, Escher F, Lassner D, K\u00fchl U, Gross U, Fruhwald F, Wenzel P, M\u00fcnzel T, Frey N, Linke RP, Schultheiss HP (2018) Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis. Eur J Heart Fail 20(4):751\u2013757","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10307_CR10","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","volume":"65","author":"C Semsarian","year":"2015","unstructured":"Semsarian C, Ingles J, Maron MS, Maron BJ (2015) New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 65(12):1249\u20131254","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10307_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.722340","volume":"25","author":"Z Cheng","year":"2021","unstructured":"Cheng Z, Fang T, Huang J, Guo Y, Alam M, Qian H (2021) Hypertrophic cardiomyopathy: from phenotype and pathogenesis to treatment. Front Cardiovasc Med 25(8):722340","journal-title":"Front Cardiovasc Med"},{"key":"10307_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.004016","volume":"128","author":"R Coppini","year":"2013","unstructured":"Coppini R, Ferrantini C, Del Lungo M, Stillitano F, Sartiani L, Tosi B et al (2013) Response to letter regarding article, late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation 128:e157","journal-title":"Circulation"},{"key":"10307_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003565","volume":"10","author":"R Coppini","year":"2017","unstructured":"Coppini R, Mazzoni L, Ferrantini C, Gentile F, Pioner JM, Laurino A et al (2017) Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy. Circ Heart Fail 10:e003565","journal-title":"Circ Heart Fail"},{"key":"10307_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005407","volume":"6","author":"C Ferrantini","year":"2017","unstructured":"Ferrantini C, Coppini R, Pioner JM, Gentile F, Tosi B, Mazzoni L et al (2017) Pathogenesis of hypertrophic cardiomyopathy is mutation rather than disease specific: a comparison of the cardiac troponin T E163R and R92Q mouse models. J Am Heart Assoc 6:e005407","journal-title":"J Am Heart Assoc"},{"key":"10307_CR15","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1111\/bph.14223","volume":"175","author":"C Ferrantini","year":"2018","unstructured":"Ferrantini C, Pioner JM, Mazzoni L, Gentile F, Tosi B, Rossi A et al (2018) Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium. Br J Pharmacol 175:2635\u20132652","journal-title":"Br J Pharmacol"},{"key":"10307_CR16","doi-asserted-by":"publisher","first-page":"8067592","DOI":"10.1155\/2018\/8067592","volume":"2018","author":"C Miceli","year":"2018","unstructured":"Miceli C, Santin Y, Manzella N, Coppini R, Berti A, Stefani M et al (2018) Oleuropein aglycone protects against MAO-A-Induced autophagy impairment and cardiomyocyte death through activation of TFEB. Oxid Med Cell Longev 2018:8067592","journal-title":"Oxid Med Cell Longev"},{"key":"10307_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1089\/ars.2015.6522","volume":"25","author":"Y Santin","year":"2016","unstructured":"Santin Y, Sicard P, Vigneron F, Guilbeau-Frugier C, Dutaur M, Lairez O et al (2016) Oxidative stress by monoamine Oxidase-A impairs transcription factor EB activation and autophagosome clearance, leading to cardiomyocyte necrosis and heart failure. Antioxid Redox Signal 25:10\u201327","journal-title":"Antioxid Redox Signal"},{"key":"10307_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004140","volume":"10","author":"SR Singh","year":"2017","unstructured":"Singh SR, Zech ATL, Geertz B, Reischmann-Dusener S, Osinska H, Prondzynski M et al (2017) Carrier, activation of autophagy ameliorates cardiomyopathy in Mybpc3-targeted knockin mice. Circ Heart Fail 10:e004140","journal-title":"Circ Heart Fail"},{"key":"10307_CR19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1161\/HYPERTENSIONAHA.113.02526","volume":"63","author":"X Xu","year":"2014","unstructured":"Xu X, Roe ND, Weiser-Evans MC, Ren J (2014) Inhibition of mammalian target of rapamycin with rapamycin reverses hypertrophic cardiomyopathy in mice with cardiomyocyte-specific knockout of PTEN. Hypertension 63:729\u2013739","journal-title":"Hypertension"},{"issue":"12","key":"10307_CR20","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.3390\/jcm8122195","volume":"8","author":"C Sacchetto","year":"2019","unstructured":"Sacchetto C, Sequeira V, Bertero E, Dudek J, Maack C, Calore M (2019) Metabolic Alterations in Inherited Cardiomyopathies. J Clin Med 8(12):2195","journal-title":"J Clin Med"},{"issue":"344","key":"10307_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ijcard.2021.09.009","volume":"1","author":"R Hassoun","year":"2021","unstructured":"Hassoun R, Budde H, Zhazykbayeva S, Herwig M, Sieme M, Delalat S, Mostafi N, G\u00f6m\u00f6ri K, Tangos M, Jarkas M, Pabel S, Bruckm\u00fcller S, Skrygan M, L\u00f3di M, Jaquet K, Sequeira V, Gambichler T, Remedios CD, Kov\u00e1cs \u00c1, Mannherz HG, M\u00fcgge A, Sossalla S, Hamdani N (2021) Stress activated signalling impaired protein quality control pathways in human hypertrophic cardiomyopathy. Int J Cardiol 1(344):160\u2013169","journal-title":"Int J Cardiol"},{"key":"10307_CR22","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1161\/CIRCRESAHA.116.308688","volume":"118","author":"L Zhao","year":"2016","unstructured":"Zhao L, Cheng G, Jin R, Afzal MR, Samanta A, Xuan Y-T, Girgis M, Elias H, Zhu Y, Davani A et al (2016) Deletion of interleukin-6 attenuates pressure overload-induced left ventricular hypertrophy and dysfunction. Circ Res 118:1918\u20131929","journal-title":"Circ Res"},{"key":"10307_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11239-019-02026-1","volume":"49","author":"RC Becker","year":"2020","unstructured":"Becker RC, Owens AP, III; Sadayappan, S. (2020) Tissue-level inflammation and ventricular remodeling in hypertrophic cardiomyopathy. J Thromb Thrombolysis 49:177\u2013183","journal-title":"J Thromb Thrombolysis"},{"key":"10307_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1161\/CIRCIMAGING.112.000110","volume":"6","author":"PE Bravo","year":"2013","unstructured":"Bravo PE, Zimmerman SL, Luo HC, Pozios I, Rajaram M, Pinheiro A, Steenbergen C, Kamel IR, Wahl RL, Bluemke DA, Bengel FM, Abraham MR, Abraham TP (2013) Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 6:210\u2013217","journal-title":"Circ Cardiovasc Imaging"},{"issue":"3","key":"10307_CR25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI156453","volume":"132","author":"DF Riascos-Bernal","year":"2022","unstructured":"Riascos-Bernal DF, Sibinga NE (2022) Neutrophil extracellular traps in cardiac hypertrophy: a KLF2 perspective. J Clin Invest 132(3):e156453","journal-title":"J Clin Invest"},{"issue":"8","key":"10307_CR26","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1053\/hupa.2000.16659","volume":"31","author":"C Basso","year":"2000","unstructured":"Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A (2000) Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 31(8):988\u2013998","journal-title":"Hum Pathol"},{"key":"10307_CR27","doi-asserted-by":"crossref","unstructured":"Lamke GT, Allen RD, Edwards WD, Tazelaar HD, Danielson GK (2003) Surgical pathology of subaortic septal myectomy associated with hypertrophic cardiomyopathy. A study of 204 cases (1996\u20132000). Cardiovasc Pathol 12:149\u2013158","DOI":"10.1016\/S1054-8807(03)00036-X"},{"key":"10307_CR28","doi-asserted-by":"crossref","unstructured":"Baandrup U, Olsen EG (1981) Critical analysis of endomyocardial biopsies from patients suspected of having cardiomyopathy. I: morphological and morphometric aspects. Br Heart J 45:475\u2013486","DOI":"10.1136\/hrt.45.5.475"},{"issue":"7","key":"10307_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007849","volume":"14","author":"YJ Shimada","year":"2021","unstructured":"Shimada YJ, Raita Y, Liang LW, Maurer MS, Hasegawa K, Fifer MA, Reilly MP (2021) Comprehensive proteomics profiling reveals circulating biomarkers of hypertrophic cardiomyopathy. Circ Heart Fail 14(7):e007849","journal-title":"Circ Heart Fail"},{"issue":"11","key":"10307_CR30","first-page":"5063","volume":"9","author":"L Fang","year":"2017","unstructured":"Fang L, Ellims AH, Beale AL, Taylor AJ, Murphy A, Dart AM (2017) Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy. Am J Transl Res 9(11):5063\u20135073","journal-title":"Am J Transl Res"},{"issue":"5","key":"10307_CR31","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.3390\/ijms22052474","volume":"22","author":"A Larson","year":"2021","unstructured":"Larson A, Libermann TA, Bowditch H, Das G, Diakos N, Huggins GS, Rastegar H, Chen FY, Rowin EJ, Maron MS, Chin MT (2021) Plasma proteomic profiling in hypertrophic cardiomyopathy patients before and after surgical myectomy reveals post-procedural reduction in systemic inflammation. Int J Mol Sci 22(5):2474","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10307_CR32","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/eurjpc\/zwab047","volume":"29","author":"F Pelliccia","year":"2022","unstructured":"Pelliccia F, Limongelli G, Rosano GMC, Vitale C, Bossone E, Calabr\u00f2 P, Gaudio C (2022) Nuclear factor-kappa B predicts long-term clinical outcome in patients with hypertrophic cardiomyopathy: 10-year follow-up study. Eur J Prev Cardiol 29(3):e108\u2013e111","journal-title":"Eur J Prev Cardiol"},{"key":"10307_CR33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1536\/ihj.46.231","volume":"46","author":"K Zen","year":"2005","unstructured":"Zen K, Irie H, Doue T, Takamiya M, Yamano T, Sawada T, Azuma A, Matsubara H (2005) Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy: comparison between nonobstructive and dilated-phase hypertrophic cardiomyopathy. Int Heart J 46:231\u2013244","journal-title":"Int Heart J"},{"key":"10307_CR34","doi-asserted-by":"publisher","unstructured":"Mohammed Arif F, Sadayappan S, Owens P, Becker R (2020) Abstract 16683: Profiling cardiac inflammation and molecular changes during the transition of hypertrophic to dilated cardiomyopathy.\u00a0142:A16683. https:\/\/doi.org\/10.1161\/circ.142.suppl_3.16683Circulation","DOI":"10.1161\/circ.142.suppl_3.16683Circulation"},{"key":"10307_CR35","doi-asserted-by":"crossref","unstructured":"Ozyilmaz S, Akgul O, Uyarel H, Pusuroglu H, Gul M, Satilmisoglu MH, Bolat I, Ozyilmaz I, U\u00e7ar H, Yildirim A, Bakir I (2017) The importance of the neutrophil-to-lymphocyte ratio in patients with hypertrophic cardiomyopathy. Rev Port Cardiol 36(4):239\u2013246. English, Portuguese","DOI":"10.1016\/j.repc.2016.09.014"},{"key":"10307_CR36","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry\u2019s disease: ceramidetrihexosidase deficiency. N Engl J Med 276:1163\u20131167","journal-title":"N Engl J Med"},{"issue":"4","key":"10307_CR37","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1136\/hrt.2005.063818","volume":"93","author":"A Linhart","year":"2007","unstructured":"Linhart A, Elliott PM (2007) The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 93(4):528\u2013535","journal-title":"Heart"},{"key":"10307_CR38","doi-asserted-by":"crossref","unstructured":"Linhart A, Kampmann C, Zamorano JL et al (2007) European FOS Investigators. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28(10):1228\u201335","DOI":"10.1093\/eurheartj\/ehm153"},{"key":"10307_CR39","doi-asserted-by":"crossref","unstructured":"O'Mahony C, Elliott P (2010) Anderson-Fabry disease and the heart. Prog Cardiovasc Dis 52(4):326\u201335","DOI":"10.1016\/j.pcad.2009.11.002"},{"key":"10307_CR40","doi-asserted-by":"crossref","unstructured":"Elleder M, Bradova V, Smid F et al (1990) Cardiocyte storage and hypertrophy as a sole manifestation of Fabry\u2019s disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 417:449\u2013455","DOI":"10.1007\/BF01606034"},{"key":"10307_CR41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1651-2227.2003.tb00222.x","volume":"92","author":"M Elleder","year":"2003","unstructured":"Elleder M (2003) Sequelae of storage in Fabry disease\u2014pathology and comparison with other lysosomal storage diseases. Acta Paediatr Suppl 92:46\u201353","journal-title":"Acta Paediatr Suppl"},{"key":"10307_CR42","doi-asserted-by":"publisher","unstructured":"Pieroni M, Ciabatti M, Graziani F, Camporeale A, Saletti E, Lillo R, Figliozzi S, Bolognese L\u00a0(2022) The heart in Fabry disease: mechanisms beyond storage and forthcoming therapies. Rev Cardiovasc Med 23(6):196. https:\/\/doi.org\/10.31083\/j.rcm2306196","DOI":"10.31083\/j.rcm2306196"},{"issue":"3","key":"10307_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","volume":"122","author":"P Rozenfeld","year":"2017","unstructured":"Rozenfeld P, Feriozzi S (2017) Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab 122(3):19\u201327","journal-title":"Mol Genet Metab"},{"key":"10307_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/8904_2014_371","volume":"22","author":"W Mauhin","year":"2015","unstructured":"Mauhin W, Lidove O, Masat E et al (2015) Innate and adaptive immune response in Fabry disease. JIMD Rep 22:1\u201310","journal-title":"JIMD Rep"},{"key":"10307_CR45","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1093\/hmg\/ddv291","volume":"24","author":"MD Sanchez-Ni\u00f1o","year":"2015","unstructured":"Sanchez-Ni\u00f1o MD, Carpio D, Sanz AB et al (2015) Lyso-Gb3 activates Notch1 in human podocytes. Hum Mol Genet 24:5720\u20135732","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10307_CR46","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","volume":"109","author":"PN De Francesco","year":"2013","unstructured":"De Francesco PN, Mucci JM, Ceci R, Fossati CA, Rozenfeld PA (2013) Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide. Mol Genet Metab 109(1):93\u201399","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10307_CR47","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1097\/01.ASN.0000121781.89599.16","volume":"15","author":"HJ Anders","year":"2004","unstructured":"Anders HJ, Banas B, Schl\u00f6ndorff D (2004) Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 15(4):854\u2013867","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10307_CR48","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","volume":"47","author":"T DeGraba","year":"2000","unstructured":"DeGraba T, Azhar S, Dignat-George F, Brown E, Bouti\u00e8re B, Altarescu G, McCarron R, Schiffmann R (2000) Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 47(2):229\u2013233","journal-title":"Ann Neurol"},{"key":"10307_CR49","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","volume":"95","author":"JS Shen","year":"2008","unstructured":"Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, Schiffmann R, Kaneski CR (2008) Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab 95:163\u2013168","journal-title":"Mol Genet Metab"},{"issue":"Suppl. 1","key":"10307_CR50","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1007\/s10545-009-1060-9","volume":"32","author":"P Rozenfeld","year":"2009","unstructured":"Rozenfeld P, Agriello E, De Francesco N, Martinez P, Fossati C (2009) Leukocyte perturbation associated with Fabry disease. J Inherit Metab Dis 32(Suppl. 1):S67-77","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"10307_CR51","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","volume":"1822","author":"GB Biancini","year":"2012","unstructured":"Biancini GB, Vanzin CS, Rodrigues DB, Deon M, Ribas GS, Barschak AG, Manfredini V, Netto CB, Jardim LB, Giugliani R, Vargas CR (2012) Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim Biophys Acta 1822(2):226\u2013232","journal-title":"Biochim Biophys Acta"},{"key":"10307_CR52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.mrgentox.2015.04.012","volume":"784\u2013785","author":"GB Biancini","year":"2015","unstructured":"Biancini GB, Moura DJ, Manini PR, Faverzani JL, Netto CB, Deon M, Giugliani R, Saffi J, Vargas CR (2015) DNA damage in Fabry patients: an investigation of oxidative damage and repair. Mutat Res Genet Toxicol Environ Mutagen 784\u2013785:31\u201336","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"issue":"461","key":"10307_CR53","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cca.2016.07.016","volume":"1","author":"GB Biancini","year":"2016","unstructured":"Biancini GB, Jacques CE, Hammerschmidt T, de Souza HM, Donida B, Deon M, Vairo FP, Louren\u00e7o CM, Giugliani R, Vargas CR (2016) Biomolecules damage and redox status abnormalities in Fabry patients before and during enzyme replacement therapy. Clin Chim Acta 1(461):41\u201346","journal-title":"Clin Chim Acta"},{"issue":"4","key":"10307_CR54","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ymgme.2013.01.018","volume":"108","author":"CS Pereira","year":"2013","unstructured":"Pereira CS, Azevedo O, Maia ML, Dias AF, Sa-Miranda C, Macedo MF (2013) Invariant natural killer T cells are phenotypically and functionally altered in Fabry disease. Mol Genet Metab 108(4):241\u2013248","journal-title":"Mol Genet Metab"},{"issue":"6","key":"10307_CR55","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1007\/s10753-015-0214-1","volume":"38","author":"Y Hayashi","year":"2015","unstructured":"Hayashi Y, Hanawa H, Jiao S, Hasegawa G, Ohno Y, Yoshida K, Suzuki T, Kashimura T, Obata H, Tanaka K, Watanabe T, Minamino T (2015) Elevated endomyocardial biopsy macrophage-related markers in intractable myocardial diseases. Inflammation 38(6):2288\u20132299","journal-title":"Inflammation"},{"issue":"17","key":"10307_CR56","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009052","volume":"7","author":"A Frustaci","year":"2018","unstructured":"Frustaci A, Verardo R, Grande C, Galea N, Piselli P, Carbone I, Alfarano M, Russo MA, Chimenti C (2018) Immune-mediated myocarditis in Fabry disease cardiomyopathy. J Am Heart Assoc 7(17):e009052","journal-title":"J Am Heart Assoc"},{"issue":"15","key":"10307_CR57","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jacc.2016.07.741","volume":"68","author":"S Nordin","year":"2016","unstructured":"Nordin S, Kozor R, Bulluck H, Castelletti S, Rosmini S, Abdel-Gadir A, Baig S, Mehta A, Hughes D, Moon JC (2016) Cardiac Fabry disease with late gadolinium enhancement is a chronic inflammatory cardiomyopathy. J Am Coll Cardiol 68(15):1707\u20131708","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10307_CR58","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1161\/CIRCHEARTFAILURE.108.769729","volume":"1","author":"C Chimenti","year":"2008","unstructured":"Chimenti C, Morgante E, Tanzilli G et al (2008) Angina in Fabry disease reflects coronary small vessel disease. Circ Heart Fail 1(3):161\u2013169","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10307_CR59","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","volume":"99","author":"SM Rombach","year":"2010","unstructured":"Rombach SM, Twickler TB, Aerts JM, Linthorst GE, Wijburg FA, Hollak CE (2010) Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab 99(2):99\u2013108","journal-title":"Mol Genet Metab"},{"key":"10307_CR60","doi-asserted-by":"crossref","unstructured":"Tomberli B, Cecchi F, Sciagr\u00e0 R et al (2013) Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabrydisease.Eur J Heart Fail 15(12):1363\u201373","DOI":"10.1093\/eurjhf\/hft104"},{"issue":"6","key":"10307_CR61","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jcmg.2012.12.011","volume":"6","author":"A Recio-Mayoral","year":"2013","unstructured":"Recio-Mayoral A, Rimoldi OE, Camici PG, Kaski JC (2013) Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. JACC Cardiovasc Imaging 6(6):660\u2013667","journal-title":"JACC Cardiovasc Imaging"},{"issue":"16","key":"10307_CR62","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2020.47","volume":"30","author":"S Godo","year":"2021","unstructured":"Godo S, Takahashi J, Yasuda S, Shimokawa H (2021) Role of inflammation in coronary epicardial and microvascular dysfunction. Eur Cardiol 30(16):e13","journal-title":"Eur Cardiol"},{"issue":"7","key":"10307_CR63","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.119.008872","volume":"12","author":"KD Knott","year":"2019","unstructured":"Knott KD, Augusto JB, Nordin S, Kozor R, Camaioni C, Xue H, Hughes RK, Manisty C, Brown LAE, Kellman P, Ramaswami U, Hughes D, Plein S, Moon JC (2019) Quantitative myocardial perfusion in Fabry disease. Circ Cardiovasc Imaging 12(7):e008872","journal-title":"Circ Cardiovasc Imaging"},{"issue":"5","key":"10307_CR64","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, Lemay R, Linthorst GE, Packman S, Scott CR, Waldek S, Warnock DG, Weinreb NJ, Wilcox WR (2015) Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet 52(5):353\u2013358","journal-title":"J Med Genet"},{"key":"10307_CR65","first-page":"401","volume":"24","author":"ES Park","year":"2009","unstructured":"Park ES, Choi JO, Park JW, Lee MH, Park HY, Jung SC (2009) Expression of genes and their responses to enzyme replacement therapy in a Fabry disease mouse model. Int J Mol Med 24:401\u2013407","journal-title":"Int J Mol Med"},{"key":"10307_CR66","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1039\/C4MB00707G","volume":"11","author":"V Matafora","year":"2015","unstructured":"Matafora V, Cuccurullo M, Beneduci A, Petrazzuolo O, Simeone A, Anastasio P, Mignani R, Feriozzi S, Pisani A, Comotti C, Bachi A, Capasso G (2015) Early markers of Fabry disease revealed by proteomics. Mol BioSyst 11:1543\u20131551","journal-title":"Mol BioSyst"},{"issue":"2","key":"10307_CR67","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/jhg.2015.123","volume":"61","author":"Y Ko","year":"2016","unstructured":"Ko Y, Lee C, Moon MH, Hong GR, Cheon CK, Lee JS (2016) Unravelling the mechanism of action of enzyme replacement therapy in Fabry disease. J Hum Genet 61(2):143\u2013149. https:\/\/doi.org\/10.1038\/jhg.2015.123. Epub 2015 Oct 22 PMID: 26490183","journal-title":"J Hum Genet"},{"issue":"1221","key":"10307_CR68","first-page":"e1","volume":"32","author":"KH Chen","year":"2016","unstructured":"Chen KH, Chien Y, Wang KL, Leu HB, Hsiao CY, Lai YH, Wang CY, Chang YL, Lin SJ, Niu DM, Chiou SH, Yu WC (2016) Evaluation of proinflammatory prognostic biomarkers for Fabry cardiomyopathy with enzyme replacement therapy. Can J Cardiol 32(1221):e1-1221.e9","journal-title":"Can J Cardiol"},{"issue":"10038","key":"10307_CR69","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN (2016) Systemic amyloidosis. Lancet 387(10038):2641\u20132654","journal-title":"Lancet"},{"key":"10307_CR70","doi-asserted-by":"crossref","unstructured":"Real de As\u00faa D, Costa R, Galv\u00e1n JM, Filigheddu MT, Trujillo D, Cadi\u00f1anos J (2014) Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol 6:369\u201377","DOI":"10.2147\/CLEP.S39981"},{"issue":"23","key":"10307_CR71","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann HJ, Goodman HJ, Gilbertson JA et al (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356(23):2361\u20132371","journal-title":"N Engl J Med"},{"key":"10307_CR72","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","volume":"112","author":"RH Falk","year":"2005","unstructured":"Falk RH (2005) Diagnosis and management of the cardiac amyloidoses. Circulation 112:2047\u20132060","journal-title":"Circulation"},{"issue":"12","key":"10307_CR73","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/17474086.2021.2003704","volume":"14","author":"M Camilli","year":"2021","unstructured":"Camilli M, La Vecchia G, Lillo R, Iannaccone G, Lamendola P, Montone RA, Hohaus S, Aspromonte N, Massetti M, Lanza GA, Crea F, Graziani F, Lombardo A (2021) Cardiovascular involvement in patients affected by multiple myeloma: a comprehensive review of recent advances. Expert Rev Hematol 14(12):1115\u20131128","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"10307_CR74","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/s41375-019-0640-4","volume":"34","author":"TL Jordan","year":"2020","unstructured":"Jordan TL, Maar K, Redhage KR, Misra P, Blancas-Mejia LM, Dick CJ, Wall JS, Williams A, Dietz AB, van Wijnen AJ, Lin Y, Ramirez-Alvarado M (2020) Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells. Leukemia 34(5):1383\u20131393","journal-title":"Leukemia"},{"issue":"1","key":"10307_CR75","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12883-019-1369-4","volume":"19","author":"EP Azevedo","year":"2019","unstructured":"Azevedo EP, Guimaraes-Costa AB, Bandeira-Melo C, Chimelli L, Waddington-Cruz M, Saraiva EM, Palhano FL, Foguel D (2019) Inflammatory profiling of patients with familial amyloid polyneuropathy. BMC Neurol 19(1):146","journal-title":"BMC Neurol"},{"issue":"1","key":"10307_CR76","doi-asserted-by":"publisher","first-page":"H149","DOI":"10.1152\/ajpheart.00073.2021","volume":"321","author":"KT Dittloff","year":"2021","unstructured":"Dittloff KT, Iezzi A, Zhong JX, Mohindra P, Desai TA, Russell B (2021) Transthyretin amyloid fibrils alter primary fibroblast structure, function, and inflammatory gene expression. Am J Physiol Heart Circ Physiol 321(1):H149\u2013H160","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"10307_CR77","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1038\/s41598-017-01775-4","volume":"7","author":"G Suenaga","year":"2017","unstructured":"Suenaga G, Ikeda T, Masuda T, Motokawa H, Yamashita T, Takamatsu K, Misumi Y, Ueda M, Matsui H, Senju S, Ando Y (2017) Inflammatory state exists in familial amyloid polyneuropathy that may be triggered by mutated transthyretin. Sci Rep 7(1):1579","journal-title":"Sci Rep"},{"key":"10307_CR78","doi-asserted-by":"crossref","unstructured":"Hein SJ, Knoll M, Aus dem Siepen F, Furkel J, Schoenland S, Hegenbart U, Katus HA, Kristen AV, Konstandin M (2021) Elevated interleukin-6 levels are associated with impaired outcome in cardiac transthyretin amyloidosis. World J Cardiol 13(3):55\u201367","DOI":"10.4330\/wjcc.v13.i3.55"},{"key":"10307_CR79","doi-asserted-by":"publisher","unstructured":"Klingel K, Hehn A, Sauter M (2017)\u00a0P5403 The impact of inflammation on the outcome of cardiac amyloidosi. Eur Heart J 38(suppl_1):ehx493.P5403.\u00a0\u00a0https:\/\/doi.org\/10.1093\/eurheartj\/ehx493.P5403","DOI":"10.1093\/eurheartj\/ehx493.P5403"},{"issue":"25","key":"10307_CR80","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1016\/j.jacc.2018.03.536","volume":"71","author":"T Kotecha","year":"2018","unstructured":"Kotecha T, Martinez-Naharro A, Treibel TA, Francis R, Nordin S, Abdel-Gadir A, Knight DS, Zumbo G, Rosmini S, Maestrini V, Bulluck H, Rakhit RD, Wechalekar AD, Gilbertson J, Sheppard MN, Kellman P, Gillmore JD, Moon JC, Hawkins PN, Fontana M (2018) Myocardial edema and prognosis in amyloidosis. J Am Coll Cardiol 71(25):2919\u20132931","journal-title":"J Am Coll Cardiol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10307-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-023-10307-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10307-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T16:29:12Z","timestamp":1691166552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-023-10307-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":80,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["10307"],"URL":"https:\/\/doi.org\/10.1007\/s10741-023-10307-4","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"assertion":[{"value":"26 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Francesca Graziani has received grants from Takeda and Pfizer; she has received honoraria for board meetings and travel support from Amicus Therapeutics, Sanofi-Genzyme, and Shire. Iacopo Olivotto has received grants from Myokardia, Sanofi Genzyme, Shire, Bayer, Amicus, and Menarini International; he has received board and\/or speaker\u2019s fees from Myokardia, Cytokinetics, Sanofi Genzyme, and Shire. Rosa Lillo has received honoraria for board meetings and travel support from Amicus Therapeutics, Sanofi-Genzyme, and Shire. The remaining authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}